It is neither a villain nor a vitamin. One value in isolation says very little, and what it means depends on the rest of your fatty acid profile, your eating pattern and the other markers tested alongside it.
It is a long chain polyunsaturated fat with 20 carbons and four double bonds, written by chemists as 20:4n-6, sitting in the omega-6 family alongside its precursor linoleic acid. Very little of it circulates free in blood. Almost all of it is built into the phospholipids that form cell membranes, with the highest concentrations in brain grey matter, platelets, white blood cells, liver and skeletal muscle, where it keeps membranes flexible and acts as a stored pool of signalling raw material.
That stored pool is the whole point. When a cell is stressed, injured or stimulated by an immune signal, an enzyme called phospholipase A2 clips the fatty acid out of the membrane, and once released it is rapidly oxidised by several enzyme families into messenger molecules that act locally and then break down within minutes 1. Those messengers influence blood vessel width, platelet clumping, pain and fever signalling, mucus production, kidney handling of salt and water, and the recruitment of immune cells into tissue.
So the fatty acid itself is not the active agent. It is the substrate. The products a tissue makes from it depend on which enzymes that tissue is running at that moment, which is why the same molecule can drive a swollen ankle, a clotting platelet and the signal that later clears the inflammation away.
From two routes, diet and internal synthesis, and for most people internal synthesis does the heavier lifting. Dietary sources are animal foods. Meat, poultry, eggs and organ meats carry the most, with smaller amounts in seafood, while plant foods contain essentially none.
The second route starts with linoleic acid, the omega-6 that dominates seed oils, nuts, seeds and many packaged foods. The body elongates and desaturates linoleic acid in a series of steps, using the same desaturase enzymes that also process omega-3 fats. Because those enzymes are shared, omega-6 and omega-3 intakes compete for the same machinery, and conversion efficiency differs from person to person because the enzymes are under genetic control and are influenced by age, sex and metabolic state.
A review of dietary surveys and clinical trials in adults reports that habitual intake from food varies considerably between populations and eating patterns 2. That same review found that research suggests intakes within the range supplied by ordinary mixed diets do not meaningfully raise circulating markers of inflammation in otherwise healthy adults 2.
The practical read is that membrane levels are not a simple mirror of how much steak or how many eggs you ate last week. They reflect total omega-6 intake, omega-3 intake, conversion capacity and how fast your tissues are using the pool.
Because it sits at the junction between cell structure and cell signalling, two jobs that most nutrients never combine. Structurally, it is one of the fats that keeps membranes fluid enough for receptors, ion channels and transporters to work, and it is especially concentrated in nervous tissue and in the retina. Without an adequate supply, normal growth, immune defence and nerve signalling are compromised.
Functionally, it is the parent of a large family of local hormones. Once released from the membrane it is oxidised into prostaglandins, thromboxanes, leukotrienes and related compounds that act on nearby cells and then disappear 1. These are the molecules behind the redness and swelling of an injury, the clotting response at a cut, menstrual cramping, airway narrowing and the fever response to infection.
The part that gets lost in popular writing is the second half of the story. Some of the products made from this same fatty acid, including the lipoxins formed through lipoxygenase enzymes, participate in closing inflammation down and clearing debris once the threat has passed. Inflammation that never starts is as much of a problem as inflammation that never stops.
That is why a result is interpreted as part of a balance rather than as a score where lower is automatically better.
Through three enzyme routes plus one non-enzymatic route, all acting on the same released molecule. This branching is what people mean by the arachidonic acid cascade, and the enzyme that happens to be most active in a given tissue decides which signals get made.
| Enzyme route | Main products | Broad role in the body |
|---|---|---|
| Cyclooxygenase (COX-1, COX-2) | Prostaglandins, thromboxanes | Platelet clumping, blood vessel tone, pain and fever signalling, protection of the stomach lining |
| Lipoxygenase (including ALOX5 and ALOX15) | Leukotrienes, HETEs, lipoxins | Immune cell recruitment, airway tone, and signals involved in resolving inflammation |
| Cytochrome P450 | EETs, 20-HETE | Blood vessel tone, kidney handling of sodium and water |
| Non-enzymatic oxidation | Isoprostanes | Formed when oxidative stress is high, used in laboratories as an oxidation marker |
The cascade is also regulated from the outside. Reactive lipid products formed during oxidation can feed back onto the enzymes that generate them, altering how much of each product is produced 1.
For a reader looking at a lab report, the useful takeaway is that the blood test measures the size of the raw material pool, not the rate at which any one branch is firing. A fatty acid percentage tells you what is available. It does not tell you what your tissues are currently doing with it.
Both things are true at once, and the pro-inflammatory label is an oversimplification. The body needs it. It is a structural component of every cell membrane you own, it is required for normal platelet function and immune defence, and the brain holds it in high concentration throughout life.
What drives the reputation is that several of the strongest inflammatory mediators are made from it, and that omega-3 fats such as EPA compete for the same enzymes and yield less inflammatory products. When the omega-6 pool is large and the omega-3 pool is small, the cascade has more substrate pointing in one direction.
That is a statement about balance, not about the fatty acid being harmful on its own. In adults, research suggests that food level intakes do not push inflammatory markers upward in healthy people 2, which is hard to reconcile with the idea that the molecule is inflammatory in any simple dose dependent way.
A more accurate mental model is a thermostat with two inputs. Omega-6 derived signals turn the response on and help orchestrate it, omega-3 derived signals moderate it and support its resolution, and the ratio between them shapes how readily the system swings. That is the reasoning behind reporting the two together rather than reporting either alone.
It shows the relative size of the omega-6 and omega-3 substrate pools competing for the same enzymes, expressed as one number. Some laboratories report arachidonic acid divided by EPA, where a higher number means relatively more omega-6. Others report EPA divided by arachidonic acid, where a higher number means relatively more omega-3. Reading the direction on your own report before interpreting it saves a lot of confusion.
The ratio has been examined most closely in heart health. Research suggests that a lower EPA to arachidonic acid ratio is associated with greater cardiovascular risk, and the ratio has been proposed as a marker with clinical utility in that setting 3.
What the ratio adds over either fatty acid alone is context. Two people can have identical arachidonic acid percentages and completely different ratios because one of them eats oily fish regularly and the other does not. The ratio captures the competition, which is closer to the biology than either number on its own.
What it does not do is diagnose anything. It is a composition measure, not a measure of inflammation in your body right now, and target values differ between laboratories and between the two ways of writing the ratio. Interpret it against the range printed on your own report, with a clinician who can see the rest of your results.
It is measured on the same red blood cell fatty acid panel. The Omega-3 Index reports EPA plus DHA as a percentage of the total fatty acids in the red cell membrane, giving a slow moving picture of omega-3 status. Typical lab reference ranges run 6 to 12 %, and FitScript's optimal range is 8 to 12 %, which is an optimization target rather than a diagnostic cut-off. Ranges vary by lab, age and sex.
Because it measures the omega-3 side of the same membrane, it usually moves in the opposite direction to the AA:EPA ratio. The parent guide covers what the index measures, how it is tested and how to read a specific result in detail.
A high arachidonic acid percentage, or a high AA:EPA ratio, most often reflects the balance of fats reaching your cell membranes rather than anything dramatic happening inside them. Common contributors include a low intake of long chain omega-3 fats, a high total omega-6 intake from oils and processed foods, an efficient personal conversion of linoleic acid, and a diet built heavily around animal fats.
Following the observation to meaning to next step pattern, here is how to read it. The observation is that the omega-6 pool is large relative to the omega-3 pool. What it may reflect is a membrane composition that favours the inflammatory arm of the cascade when the system is activated, which is a tendency rather than an event. What is worth doing is bringing the result to a clinician alongside your other markers, because the number only becomes meaningful next to inflammation, lipid and metabolic results.
What a high value does not do is tell you that you have an inflammatory condition, heart disease or any other diagnosis. Fatty acid composition is one input among many. It is also modifiable, which is part of why people test it, and any change in eating pattern or supplementation is a decision to make with a clinician or dietitian who knows your history, not from a percentage on a page.
Low arachidonic acid usually points to limited supply or limited conversion rather than to anything protective. Possible contributors include a very low total fat intake, a diet with little animal food and little omega-6, reduced desaturase and elongase activity, fat malabsorption, or a very high omega-3 intake displacing omega-6 from membranes.
It is worth saying plainly that lower is not automatically better here. The fatty acid is required for membrane structure, platelet function, immune competence and nervous tissue, so a value sitting well below the laboratory range is a suboptimal finding in its own right and is worth discussing with a clinician rather than celebrating.
In practice, low values are seen less often than high ones on routine panels, because most modern eating patterns supply plenty of omega-6. When a low value does appear, the useful next questions are about overall dietary fat intake, digestion and absorption, and whether supplementation has shifted the balance a long way in one direction. A clinician can decide whether any further testing is warranted and what, if anything, should change.
If a low result appears together with symptoms such as unexplained weight loss, persistent digestive problems or poor wound healing, that combination is worth discussing with a clinician promptly rather than at your next routine review.
Several things, and most of them are slow moving. The main influences are the total amount of omega-6 in the diet, the amount of long chain omega-3 reaching the membranes, and how efficiently your own enzymes convert linoleic acid into longer chain products. Because those enzymes are shared across both fat families, a change on one side shifts the other.
Other factors matter at the margins. Age and sex influence desaturase activity. Body composition and insulin signalling affect fatty acid handling. Alcohol intake, smoking and overall oxidative load influence how much of the released fatty acid is oxidised non-enzymatically into isoprostanes rather than processed by enzymes.
Enzyme activity in the cascade itself can also shift with metabolic health. In a review of the lipoxygenase enzyme ALOX15, altered activity of this arm of the pathway is associated with diabetes mellitus and with the inflammatory changes that accompany it 5.
The timescale matters for anyone planning to retest. Red cell membranes turn over across several months, so a red blood cell fatty acid result reflects a season of eating rather than a week of it. Plasma based measures move faster and are more sensitive to recent meals, which is exactly why the two sample types are not interchangeable.
Through a fatty acid panel that measures the fat composition of a blood sample by gas chromatography and reports each fatty acid as a percentage of the total, not as a concentration. Three sample types are common. Red blood cell membrane analysis reflects intake over the preceding months. Plasma or serum phospholipid analysis reflects more recent intake. Dried blood spot collection from a finger stick is used by several laboratories and is convenient for home collection.
Because results are percentages, every value is relative. If one fatty acid rises, something else falls, which is another reason the AA:EPA ratio is often more informative than a single percentage.
Preparation requirements differ by laboratory. Some ask for a fasting sample, many do not, and most ask that you follow your usual eating pattern in the days before collection rather than changing it for the test. Recent high dose fish oil or a very unusual week of eating can shift plasma results noticeably. Follow the instructions printed with your own kit, since they are what the laboratory's reference range assumes.
Results are reported next to that laboratory's own reference ranges, which are typical population ranges rather than targets, and they vary by lab, age and sex. For repeat testing, spacing samples several months apart gives membrane composition time to actually change.
The clearest connection runs through the balance with EPA rather than through the omega-6 value alone. Research suggests that the EPA to arachidonic acid ratio carries information about cardiovascular risk and has been studied as a clinically useful marker in that context 3.
There is also work in heart failure specifically. Research suggests that, in heart failure, arachidonic acid and the metabolites generated from it carry prognostic significance and participate in the processes that shape how the heart muscle remodels 4.
The plausible mechanism is not mysterious. Products of the cascade act directly on platelets and on blood vessel tone, and the cytochrome P450 branch influences vascular and kidney function. A membrane composition that favours one branch over another is a reasonable thing to measure if you are interested in cardiovascular biology.
None of this makes a fatty acid panel a cardiovascular risk assessment. It is one input, and it sits well behind blood pressure, lipid particle measures, blood sugar control and family history in terms of what a clinician weighs. Where it earns its place is in explaining why two people with similar standard lipid panels can have different inflammatory tendencies, and in giving a measurable handle on something that eating patterns genuinely move.
The pathway has been examined well beyond the heart, mostly through the enzymes and metabolites rather than the parent fatty acid. In metabolic health, altered activity of the ALOX15 enzyme that acts on this fatty acid is associated with diabetes mellitus and the chronic inflammation that accompanies it 5.
In the nervous system, a systematic review found that the arachidonic acid pathway is associated with the inflammatory and demyelinating processes seen in multiple sclerosis 6. In mood, metabolites of this fatty acid are associated with the neuroinflammatory changes described in major depressive disorder 7.
Read those findings carefully. They describe biology observed in groups of people with defined conditions. They do not mean that a particular percentage on your own report indicates a condition, and no fatty acid result can establish whether someone has diabetes, multiple sclerosis or depression. Those are clinical diagnoses that a qualified clinician makes using history, examination and the appropriate tests.
What the breadth of this work does justify is treating the pathway as a general purpose signalling system rather than a heart specific one. It is involved wherever inflammation is involved, which is most of the body, and that is a reason to interpret the marker in context rather than as a standalone score.
The ones that tell you what the inflammatory and metabolic environment actually looks like, because fatty acid composition only describes the raw material. A fatty acid panel read next to inflammation, lipid and glucose markers gives a far more interpretable picture than one read alone.
| Marker | What it adds next to a fatty acid result |
|---|---|
| Omega-3 Index | The omega-3 side of the same membrane, which sets the ratio |
| EPA and DHA reported separately | Shows whether omega-3 status is driven by one fatty acid or both |
| High sensitivity CRP | A general measure of current inflammatory activity in the body |
| Triglycerides | Responds to dietary fat and carbohydrate handling, and to omega-3 status |
| Fasting insulin and HbA1c | Metabolic context, since glucose handling and inflammation travel together |
| Uric acid | Another diet responsive marker tied to inflammatory and metabolic health |
| ApoB or LDL particle number | Lipid risk context that a fatty acid percentage cannot provide |
This is also where a broad panel beats single marker testing. FitScript tests 150+ biomarkers per year, and Atlas, its AI health advisor, reads them together rather than one result at a time. Seeing an elevated omega-6 to omega-3 balance alongside a normal CRP tells a different story from seeing it alongside a raised one, and that difference is what shapes the conversation with a clinician.
Any time a result sits outside your laboratory's range, any time it is changing in a direction you did not expect, and before you make a meaningful change based on it. A fatty acid percentage is an input into a clinical conversation, not an instruction.
Bring the full report rather than the single line. A clinician will want to see the ratio, the omega-3 side, your inflammatory and lipid markers, your medical history and what you actually eat. Results that arrive with symptoms deserve more urgency. Chest pain, breathlessness, unexplained swelling, persistent unexplained pain or new neurological symptoms are worth discussing with a clinician promptly, regardless of what any fatty acid number says.
If a change in diet, supplementation or any other intervention is being considered, a licensed provider evaluates whether it is appropriate for you after reviewing your results and your history. That includes decisions about anything prescription based, which are always made by a licensed provider rather than from a lab value alone. Never ignore a result that falls outside the standard range because a single article described it as common.
This page is educational and not medical advice. Discuss your own results and any treatment decision with a clinician or licensed provider who can see your full picture.
Related reading on FitScript covers the markers that sit closest to this one. The guide to triglycerides explains a lipid marker that moves with dietary fat and carbohydrate handling, and the guide to c reactive protein covers the most widely used measure of current inflammatory activity. If uric acid came up on your panel, the articles on foods high in uric acid and how to test uric acid levels cover that marker and the diet patterns connected to it.
No. It is a required component of cell membranes and the starting material for signals your body uses to run and then resolve inflammation, so you cannot do without it. What matters on a lab report is its balance with omega-3 fats rather than the value alone. A clinician interprets that balance alongside your other markers.
Animal foods carry it, with the highest amounts in meat, poultry, eggs and organ meats, and smaller amounts in seafood. Plant foods contain essentially none, although many plant oils supply linoleic acid, which the body can convert into it. Any decision about changing your eating pattern is best made with a clinician or dietitian who knows your history.
There is no single universal target, and the answer depends on which way your laboratory writes the ratio. Some labs divide arachidonic acid by EPA and others divide EPA by arachidonic acid, so the same biology can look like a high number on one report and a low number on another. Read your result against the range printed on your own report and go through it with a clinician.
No. The test measures the composition of the fat in your cell membranes, which is the raw material for inflammatory signals, not the amount of inflammation happening right now. A marker such as high sensitivity CRP is closer to measuring current inflammatory activity. Reading the two together is more informative than reading either alone.
It depends on the laboratory and the sample type. Some ask for a fasting sample, many do not, and most prefer that you keep to your normal eating pattern in the days before collection rather than changing it for the test. Follow the instructions supplied with your own kit, because the reference range assumes you did.
Red blood cell membranes change slowly over months, so retesting too soon tends to show noise rather than real change. Spacing samples several months apart gives membrane composition time to shift. Your clinician can advise on timing based on why you are tracking it.
Yes. A value well below the laboratory range is a suboptimal finding, because this fatty acid is needed for membrane structure, platelet function, immune defence and nervous tissue. Low values can follow a very low fat intake, poor fat absorption or a very heavy omega-3 intake. It is worth discussing with a clinician rather than assuming that lower is better.
Take the whole report, not the single line, to a clinician. The ratio with EPA, your omega-3 status, your inflammatory and lipid markers and your medical history all change how the value should be read. If the result comes with symptoms, raise it with a clinician promptly rather than waiting for a routine review.